Neuroscientific Biopharmaceuticals Ltd. engages in researching and developing novel peptide-based pharmaceutical products. It's research and development program is focused on developing a treatment for stroke-related brain injury and dementia or Alzheimer's disease, and a diagnostic for early-stage Alzheimer's disease. The company was founded by William Harold Clough on November 14, 2002 and is headquartered in Nedlands, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company